

**SUPPLEM ENTAL FIGURE 3.** NK cell requirement for the optimal induction of DC1s with a high capacity to induce melanoma-antigen-specific CTLs. IL-18/IFN $\alpha$ /poly-l:C-stimulated DCs in the absence or presence (NKDC1s) of autologous NK cells from HLA-A2<sup>+</sup> stage III and stage IV melanoma patients were pulsed with HLA-A2-restricted melanoma-associated peptides and used to sensitize autologous CD8<sup>+</sup> T cells. CTLs were assayed on day 24 of culture. A, Frequencies of IFN $\gamma$ -producing CD8<sup>+</sup> T cells responsive to T2 cells loaded with individual peptides, as determined by ELISPOT assay. Data recorded as the mean ( $\pm$  SD) of triplicate cultures. Data shown is from one representative experiment of three performed. \*\*\*p<0.001, ns: p>0.05. B, Flow cytometric analysis showing percentage of tetramer-positive MART-1-specific CD8<sup>+</sup> T cells generated through *in vitro* stimulation with melanoma peptide-pulsed, differentially-activated DCs. Inset numbers represent percent CD8<sup>+</sup>MART-1<sup>+</sup> cells. Results from one representative experiment of three performed.